Grants Funded
ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.
Research Abstracts
Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.
In Utero Gene Therapy Repair of Cleft Palate in a Congenital Caprine Model
Principal Investigator
Shawkat Sati MD
Shawkat Sati MD
Year
2008
2008
Institution
Lahey Clinic
Lahey Clinic
Funding Mechanism
Basic Research Grant
Basic Research Grant
Focus Area
Cranio/Maxillofacial/Head and Neck
Cranio/Maxillofacial/Head and Neck
Abstract
The proposed study will utilize the only existing congenital cleft palate model that can be repaired in utero, which has been developed and characterized over the past ten years. The long-term objectives of this study are: (1) to elucidate the mechanism of cleft palate development in humans; (2) to improve the clinical management of cleft palate and treatment of resultant secondary midface hypoplasia; and (3) develop tissue-engineered gene and cell based therapies to treat patients with cleft palate; and 4) to prevent cleft palate development in humans. The specific aims of this study are: (1) to assess the bone-producing potential of palatal shelf mucoperiosteum (lining) following in utero cleft repair in a caprine model; and (2) to evaluate and compare midfacial growth and palatal development following in utero surgical repair and after in utero BMP gene therapy. To accomplish these goals, gene therapy with BMP will be compared to surgical repair of in utero cleft palate in a caprine model. Our hypothesis is that the composite DNA plasmid and biodegradable delivery system with rhBMP-4 will promote bone regeneration equivalent if not superior to that after cleft palate repair in a fetal caprine model.
The proposed study will utilize the only existing congenital cleft palate model that can be repaired in utero, which has been developed and characterized over the past ten years. The long-term objectives of this study are: (1) to elucidate the mechanism of cleft palate development in humans; (2) to improve the clinical management of cleft palate and treatment of resultant secondary midface hypoplasia; and (3) develop tissue-engineered gene and cell based therapies to treat patients with cleft palate; and 4) to prevent cleft palate development in humans. The specific aims of this study are: (1) to assess the bone-producing potential of palatal shelf mucoperiosteum (lining) following in utero cleft repair in a caprine model; and (2) to evaluate and compare midfacial growth and palatal development following in utero surgical repair and after in utero BMP gene therapy. To accomplish these goals, gene therapy with BMP will be compared to surgical repair of in utero cleft palate in a caprine model. Our hypothesis is that the composite DNA plasmid and biodegradable delivery system with rhBMP-4 will promote bone regeneration equivalent if not superior to that after cleft palate repair in a fetal caprine model.